Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress).

Amna Falak Sher,Justine Yang Bruce,Nashat Y. Gabrail,Ian Anderson,Anna Patrikidou,Rachel E. Sanborn,Jae Yong Cho,Arielle Shebay Lee,Jong Seok Lee,Louise M. Nott,Do-Youn Oh,Sang Cheul Oh,Sung Yong Oh,Yinghui Wang,Zejing Wang,Troy H. Guthrie

Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress).

2021

Amna Falak Sher
Justine Yang Bruce
Nashat Y. Gabrail
Ian Anderson
Anna Patrikidou
Rachel E. Sanborn
Jae Yong Cho
Arielle Shebay Lee
Jong Seok Lee
Louise M. Nott
Do-Youn Oh
Sang Cheul Oh
Sung Yong Oh
Yinghui Wang
Zejing Wang
Troy H. Guthrie

TPS185Background: LIV-1 is a transmembrane protein expressed in a variety of cancer types. SGN-LIV1A, or ladiratuzumab vedotin (LV), is a novel investigational humanized IgG1 antibody-drug conjugat...

Keywords:

Oncology
Prostate cancer
castration resistant
Medicine
Internal medicine
Phases of clinical research
open label

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations